1.78
+0.03(+1.71%)
Currency In USD
| Previous Close | 1.75 |
| Open | 1.76 |
| Day High | 1.79 |
| Day Low | 1.75 |
| 52-Week High | 4.36 |
| 52-Week Low | 1.48 |
| Volume | 57,075 |
| Average Volume | 276,700 |
| Market Cap | 199.46M |
| PE | -4.56 |
| EPS | -0.39 |
| Moving Average 50 Days | 1.96 |
| Moving Average 200 Days | 2.74 |
| Change | 0.03 |
If you invested $1000 in Waldencast plc (WALD) since IPO date, it would be worth $180.71 as of September 16, 2025 at a share price of $1.78. Whereas If you bought $1000 worth of Waldencast plc (WALD) shares 3 years ago, it would be worth $209.41 as of September 16, 2025 at a share price of $1.78.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand
GlobeNewswire Inc.
Sep 10, 2025 10:45 AM GMT
U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable MarketLONDON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (N
Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive Transformation
GlobeNewswire Inc.
Aug 18, 2025 9:43 PM GMT
Obagi Medical delivers H1 2025 double-digit growth in its Core Strategic Channels. Novaestiq Acquisition Doubles the Brand’s Addressable Market in the U.S. Milk Makeup Delivers Strong Retail Sales Performance in U.S. Retail in H1 2025 and Expands Its
Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand
GlobeNewswire Inc.
Jul 23, 2025 10:45 AM GMT
Acquisition strengthens Obagi Medical’s product portfolio with proven, scientifically backed, injectable portfolio New products position Obagi Medical at the forefront of health, beauty and aesthetics convergence LONDON, July 23, 2025 (GLOBE NEWSWI